Ulobetasol lotion - Sun Pharmaceutical Industries

Drug Profile

Ulobetasol lotion - Sun Pharmaceutical Industries

Alternative Names: Halobetasol propionate lotion- Sun Pharmaceutical Industries; HBP lotion- Sun Pharmaceutical Industries; Ultravate

Latest Information Update: 18 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sun Pharmaceutical Industries
  • Class Anti-inflammatories; Antiallergics; Antipsoriatics; Corticosteroids; Skin disorder therapies; Small molecules
  • Mechanism of Action Phospholipase A2 inhibitors; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Plaque psoriasis
  • Phase II Atopic dermatitis

Most Recent Events

  • 09 May 2018 Sun Pharmaceutical Industries and MiCal Pharmaceuticals initiates litigation against Perrigo Company over ANDA submission in USA
  • 15 Feb 2018 Sun Pharmaceutical Industries Limited suspends patient enrolment in a phase II trial due to sponsor's decision in Atopic dermatitis (In children, In adolescents, In adults, In the elderly) in USA (Topical, Spray) (NCT03245385)
  • 15 Feb 2018 Sun Pharmaceutical withdraws a phase II trial prior to enrolment in Plaque psoriasis (In children, In adolescents, In adults, In the elderly) due to sponsor’s decision (Topical) (NCT03298581)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top